Psychedelic stocks are becoming just as popular with investors.
All as drugs, like psilocybin show promise in treating a range of mental health issues, including obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, eating disorders, depression and anxiety. Better, the US FDA has already referred to psilocybin as “breakthrough therapy” and multiple studies are showing positive results.
For example, as noted by NPR, a study from JAMA Psychiatry recently found that psilocybin “worked better than the usual antidepressant medications.” Even researchers from the University of California David found that micro-dosing with psychedelic drugs for a prolonged period of time showed promise.
In addition, we’re seeing broad support in the U.S. with Oregon, Denver, Oakland, and Santa Cruz legalizing the use of psilocybin, too.
As the story unfolds, some of the top stocks to keep on radar are Compass Pathways (CMPS), Numinus Wellness (NUMI), and Mind Medicine (MMEDF).
